|
1
|
Dellaretti M, Reyns N, Touzet G, Dubois F,
Gusmao S, Pereira JL and Blond S: Diffuse brainstem glioma:
Prognostic factors. J Neurosurg. 117:810–814. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grossman SA, Ye X, Piantadosi S, Desideri
S, Nabors LB, Rosenfeld M and Fisher J; NABTT CNS Consortium, :
Survival of patients with newly diagnosed glioblastoma treated with
radiation and temozolomide in research studies in the United
States. Clin Cancer Res. 16:2443–2449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y and Jiang T: Understanding high
grade glioma: Molecular mechanism, therapy and comprehensive
management. Cancer Lett. 331:139–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baker GJ, Yadav VN, Motsch S, Koschmann C,
Calinescu AA, Mineharu Y, Camelopiragua S, Orringer D, Bannykh S,
Nichols WS, et al: Mechanisms of glioma formation: Iterative
perivascular glioma growth and invasion leads to tumor progression,
VEGF-independent vascularization, and resistance to antiangiogenic
therapy. Neoplasia. 16:543–561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meng Z, Moroishi T and Guan KL: Mechanisms
of Hippo pathway regulation. Genes Dev. 30:1–17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mo J, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Rep.
15:642–656. 2014.PubMed/NCBI
|
|
8
|
Wang Y, Pan P, Wang Z, Zhang Y, Xie P,
Geng D, Jiang Y, Yu R and Zhou X: β-catenin-mediated YAP signaling
promotes human glioma growth. J Exp Clin Cancer Res. 36:1362017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bhat KP, Salazar KL, Balasubramaniyan V,
Wani K, Heathcock L, Hollingsworth F, James J, Gumin J, Diefes K,
Kin SH, et al: The transcriptional coactivator TAZ regulates
mesenchymal differentiation in malignant glioma. Genes Dev.
25:2594–2609. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grzmil M, Morin P Jr, Lino MM, Merlo A,
Frank S, Wang Y, Moncayo G and Hemmings BA: MAP kinase-interacting
kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human
glioblastoma. Cancer Res. 71:2392–2402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo C, Wang X and Liang L: LATS2-mediated
YAP1 phosphorylation is involved in HCC tumorigenesis. Int J Clin
Exp Pathol. 8:1690–1697. 2015.PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Piccolo S, Dupont S and Cordenonsi M: The
Biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev.
94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J, Chen X, Ding X, Cheng Y, Zhao B, Lai
ZC, Al-Hezaimi K, Hakem R, Guan KL and Wang CY: LATS2 suppresses
oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.
Cell Rep. 5:1650–1663. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Pei J, Xia H, Ke H, Wang H and Tao
W: Lats2, a putative tumor suppressor, inhibits G1/S transition.
Oncogene. 22:4398–4405. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bonelli P, Tuccillo FM, Borrelli A,
Schiattarella A and Buonaguro FM: CDK/CCN and CDKI alterations for
cancer prognosis and therapeutic predictivity. Biomed Res Int.
2014:3610202014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu FX, Zhao B and Guan KL: Hippo pathway
in organ size control, tissue homeostasis, and cancer. Cell.
163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Visser S and Yang X: LATS tumor
suppressor: A new governor of cellular homeostasis. Cell Cycle.
9:3892–3903. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ostrom QT, Kinnersley B, Wrensch MR,
Eckel-Passow JE, Armstrong G, Rice T, Chen YW, Wiencke J, McCoy LS,
Hansen HM, et al: Sex-specific glioma genome-wide association study
identifies new risk locus at 3p21.31 in females, and finds
sex-differences in risk at 8q24.21. Sci Rep. 8:73522018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hughes PE, Caenepeel S and Wu LC: Targeted
therapy and checkpoint immunotherapy combinations for the treatment
of cancer. Trends Immunol. 37:462–476. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Furth N and Aylon Y: The LATS1 and LATS2
tumor suppressors: Beyond the Hippo pathway. Cell Death Differ.
24:1488–1501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao Y, Yi J, Zhang K, Bai F, Feng B, Wang
R, Chu X, Chen L and Song H: Downregulation of MiR-31 stimulates
expression of LATS2 via the hippo pathway and promotes
epithelial-mesenchymal transition in esophageal squamous cell
carcinoma. J Exp Clin Cancer Res. 36:1612017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Hu CF, Chen J, Yan LX, Zeng YX
and Shao JY: LATS2 is de-methylated and overexpressed in
nasopharyngeal carcinoma and predicts poor prognosis. BMC Cancer.
10:5382010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aylon Y, Michael D, Shmueli A, Yabuta N,
Nojima H and Oren M: A positive feedback loop between the p53 and
Lats2 tumor suppressors prevents tetraploidization. Genes Dev.
20:2687–2700. 2006. View Article : Google Scholar : PubMed/NCBI
|
